Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNY4 pseudogene 7 (RNY4P7)
- Target
- RNY4P7
- Molecular classification
- Pseudogene, Non-coding RNA (pseudogene-derived RNA), Processed pseudogene (based on sequence and classification methodologies for YRNA pseudogenes[7])
01
Overview
RNY4 pseudogene 7 (RNY4P7) is a *processed, non-coding RNA pseudogene* highly homologous to the canonical RNY4 YRNA gene. YRNAs are small non-coding RNAs (~100 nucleotides) involved in RNA quality control, cellular stress response, and DNA replication. RNY4P7, along with several other RNY4 pseudogenes, is detected in human genomic DNA and transcripts from these regions may be present in small RNA sequencing studies, especially in cancer contexts. However, unlike the functional RNY4 gene and protein-coding pseudogenes that may have regulatory roles, there is no strong evidence that RNY4P7 has a distinct molecular or pathogenic function. Its presence in exosomal RNA fractions used for cancer biomarker research reflects its sequence similarity and abundant transcription rather than a specific, validated functional role. RNY4P7 is *not considered a therapeutic target* (it does not encode a protein, receptor, or active enzyme) and currently has no direct clinical applications aside from its contribution to the profile of YRNA-derived RNA in research settings[1][4][5][7].
- Other names
- RNY4P7RNA, Ro-associated Y4 pseudogene 7RNY4 pseudogene 7
02
Mechanism of action
N/A (not a drug target)
03
Biological functions
No direct biological function has been established for RNY4P7 itself. However, closely related YRNAs and their pseudogene transcripts may play regulatory roles, often through competing endogenous RNA (ceRNA) mechanisms or by interacting with RNA-binding proteins[2][7].There is insufficient evidence to ascribe a specific function to RNY4P7 as distinct from RNY4 or other pseudogenes in the family.
04
Disease associations
Potential *biomarker* relevance in lymphoma, specifically pediatric anaplastic large cell lymphoma, is reported for RNY4 and its pseudogenes as a class, given their presence in extracellular vesicles (EVs) and exosomes from patient samples[1][4].RNY4P7 is not known to be a driver of disease or a direct contributor to pathogenesis, but as part of the broader set of YRNA pseudogenes, it is included in RNA profiling studies relating to cancer[1][4].
05
Biomarkers
Not individually established as a biomarker.The *family* of RNY4 and its pseudogenes (including RNY4P7) shows increased presence in exosomes from patients with certain cancers (e.g., ALCL), supporting their use as *collective* non-coding RNA biomarkers in liquid biopsy, though measurement typically refers to the entire group rather than RNY4P7 specifically[1][4].
Beyond the preview
Go deeper on RNY4 pseudogene 7 (RNY4P7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNY4 pseudogene 7 (RNY4P7).